Cost Effectiveness of Long-Term Treatment with Eszopiclone for Primary Insomnia in Adults

No abstract is available for this paper.

• Publication year

  2007

• Venue

  CNS Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.2165/00023210-200721040-00005PMID 17381185
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An economic evaluation of rizatriptan in the treatment of migraine

  2012cited by this paper
• Sleep problems and their correlates in a working population

  2007cited by this paper
• Clinical practice. Chronic insomnia.

  2005cited by this paper
• National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005.

  2005cited by this paper
• Cost‐Effectiveness of Topiramate in Migraine Prevention: Results From a Pharmacoeconomic Model of Topiramate Treatment

  2005cited by this paper
• Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.

  2004cited by this paper
• Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.

  2004cited by this paper
• Health, Absence, Disability, and Presenteeism Cost Estimates of Certain Physical and Mental Health Conditions Affecting U.S. Employers

  2004cited by this paper
• Predicting EuroQoL EQ-5D Preference Scores from the SF-12 Health Survey in a Nationally Representative Sample

  2004cited by this paper
• Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia.

  2004cited by this paper
• The Application of Two Health and Productivity Instruments at a Large Employer

  2004cited by this paper
• Mapping the SF-12 to the EuroQol EQ-5D Index in a National US Sample

  2004cited by this paper
• Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

  2004cited by this paper
• An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.

  2004cited by this paper
• Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.

  2003cited by this paper
• Insomnia causes, consequences, and therapeutics: An overview

  2003cited by this paper
• The Health and Productivity Cost Burden of the “Top 10” Physical and Mental Health Conditions Affecting Six Large U.S. Employers in 1999

  2003cited by this paper
• Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia

  2003cited by this paper
• Lost Productive Work Time Costs From Health Conditions in the United States: Results From the American Productivity Audit

  2003cited by this paper
• Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.

  2003cited by this paper
• Insomnia: epidemiology, characteristics, and consequences.

  2003cited by this paper
• PHP35: AN ANALYSIS OF THE HEALTH AND PRODUCTIVITY COST BURDEN OF THE PHYSICAL AND MENTAL HEALTH CONDITIONS AFFECTING SIX LARGE CORPORATIONS IN 1999

  2003cited by this paper
• Prevalence of sleep problems and quality of life in an older population.

  2002cited by this paper
• Medical and socio-professional impact of insomnia.

  2002cited by this paper
• Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study

  2002cited by this paper
• Epidemiology of insomnia: what we know and what we still need to learn.

  2002cited by this paper
• The relationship between chronically disrupted sleep and healthcare use.

  2002cited by this paper
• The estimation of a preference-based measure of health from the SF-36.

  2002cited by this paper
• The relationship between insomnia and health-related quality of life in patients with chronic illness.

  2002cited by this paper
• Epidemiology of severe insomnia and its consequences in Germany

  2001cited by this paper
• SF-36: Evaluation of Quality of Life in Severe and Mild Insomniacs Compared With Good Sleepers

  2001cited by this paper
• Evaluating Quality-Adjusted Life Years

  2001cited by this paper
• CONSENSUS FOR THE PHARMACOLOGICAL MANAGEMENT OF INSOMNIA IN THE NEW MILLENNIUM

  2001cited by this paper
• Primary versus secondary insomnia in older adults: subjective sleep and daytime functioning.

  2001cited by this paper
• The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches

  2001cited by this paper
• Eight weeks of non-nightly use of zolpidem for primary insomnia.

  2000cited by this paper
• Willingness to Pay for a Quality-adjusted Life Year

  2000cited by this paper
• Antiviral therapies for herpes zoster infections. Are they economically justifiable?

  2000cited by this paper
• Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I.

  1999cited by this paper
• Loss of work productivity due to illness and medical treatment.

  1999cited by this paper
• Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and Medicine

  1999cited by this paper
• Quality of life in people with insomnia.

  1999cited by this paper
• Cost‐effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model

  1998cited by this paper
• Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption

  1998cited by this paper
• Predicting Quality of Well-being Scores from the SF-36

  1997cited by this paper
• Prevalence, burden, and treatment of insomnia in primary care.

  1997cited by this paper
• An Economic Evaluation of Finasteride for Treatment of Benign Prostatic Hyperplasia

  1996cited by this paper
• Zopiclone, sleep and health‐related quality of life

  1994cited by this paper
• Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

  1993cited by this paper
• The International Classification of Sleep Disorders

  1991cited by this paper
• Probabilistic Sensitivity Analysis Using Monte Carlo Simulation

  1985cited by this paper

• A Systematic Review of Economic Evaluations on Interventions Targeting Insomnia or Hypersomnia

  2025cites this paper
• Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review

  2024cites this paper
• Health Economics of Sleep Disorders

  2022cites this paper
• Patterns of sleep disorders after a new coronavirus infection COVID-19

  2022cites this paper
• Effects of cognitive behavioral therapy for insomnia (CBT-I) on quality of life: A systematic review and meta-analysis.

  2022influential citation
• Health-related quality of life and compensating income variation for 18 health conditions in Iceland

  2020cites this paper
• Trends of cost-effectiveness studies in sleep medicine.

  2019cites this paper
• Will Improving My Marriage Improve My Sleep?

  2019cites this paper
• Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort

  2018cites this paper
• DYNAMICS OF LIFE QUALITY, ANXIETY AND DEPRESSION SYMPTOMS AMONG PATIENTS WITH CHRONIC INSOMNIA IN COMPLEX SANATORIUM-AND-HEALTH RESORT TREATMENT WITH INCLUSION OF TRANSCRANIAL MAGNETOTHERAPY

  2018cites this paper
• Prognosis and Complications

  2017cites this paper
• Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury.

  2016cites this paper
• Subjective and Objective Daytime Consequences of Insomnia

  2016cites this paper
• Health economics of insomnia treatments: The return on investment for a good night's sleep.

  2016cites this paper
• Assessment and Management of Insomnia

  2015cites this paper
• Coste-utilidad de asenapina frente a olanzapina para el tratamiento de los episodios maniacos de pacientes con trastorno bipolar tipo I

  2015cites this paper
• Subjective–objective sleep discrepancy among older adults: associations with insomnia diagnosis and insomnia treatment

  2015cites this paper
• Quality-adjusted life-years gain and health status in patients with OSAS after one year of continuous positive airway pressure use.

  2014cites this paper
• The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers

  2014cites this paper
• Economic evaluation of benzodiazepines versus cognitive behavioural therapy among older adults with chronic insomnia

  2013cites this paper
• The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

  2013cites this paper
• Eszopiclone for insomnia.

  2013cites this paper
• Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

  2013cites this paper
• The occupational impact of sleep quality

  2013cites this paper
• Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

  2012cites this paper
• Chronic insomnia, quality-of-life, and utility scores: comparison with good sleepers in a cross-sectional international survey.

  2012cites this paper
• Eszopiclone

  2012cites this paper
• The occupational impact of sleep quality and insomnia symptoms.

  2012cites this paper
• Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities

  2011cites this paper
• Eszopiclone: an update on its use in insomnia.

  2011cites this paper
• The societal costs of insomnia

  2010influential citation
• Patients with treatment-resistant insomnia taking nightly prescription medications for sleep: a retrospective assessment of diagnostic and treatment variables.

  2010cites this paper
• Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.

  2010cites this paper
• Insomnia risks and costs: health, safety, and quality of life.

  2010cites this paper
• Insomnia-related comorbidities and economic costs among a commercially insured population in the United States

  2009cites this paper
• Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.

  2009cites this paper
• Health economics of insomnia therapy: implications for policy.

  2009cites this paper
• Insomnia: A Review of the Use of eszopiclone

  2009cites this paper
• The role of eszopiclone in the treatment of insomnia

  2009cites this paper
• Spotlight on Eszopiclone in Insomnia

  2008cites this paper
• HealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases

  2008cites this paper
• The Circuitous Route to Diagnosing Sleep Disorders in Women: Health Care Utilization and Benefits of Improved Awareness for Sleep Disorders

  2008cites this paper
• Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005.

  2008cites this paper
• Will insomnia treatments produce overall cost savings to commercial managed-care plans? A predictive analysis in the United States*

  2007cites this paper